

Results of Competition: Advanced Therapy Treatment Centres: Network Projects

Competition Code: 1806_ATTTC_NETWORK

Total available funding is £5.9m

Note: These proposals have succeeded in the assessment stage of this competition. All are subject to grant offer and conditions being met.

Participant organisation names	Project title	Proposed project costs	Proposed project grant
University Hospitals Birmingham NHS Foundation Trust	Patient-reported outcomes assessment to support accelerated access to advanced cell and gene therapies: PROmics	£105,405	£105,405
CELL THERAPY CATAPULT LIMITED		£63,820	£63,820
DATATRIAL LIMITED		£112,729	£78,910
DIGNIO LIMITED		£590,400	£413,280
The Christie NHS Foundation Trust		£25,976	£25,976
The Newcastle upon Tyne Hospitals NHS Foundation Trust		£30,320	£30,320
University of Birmingham		£471,690	£471,690
Velindre NHS Trust		£0	£0

Note: you can see all Innovate UK-funded projects here: <https://www.gov.uk/government/publications/innovate-uk-funded-projects>

Use the Competition Code given above to search for this competition's results

Project description - provided by applicants

Cell or gene therapies show great potential in treating patients with conditions that cannot be cured with current treatments. These include arthritis, liver disease, several types of cancer, and diabetic ulcers. It is important to assess the impact of these new therapies on patient quality of life and symptoms, both at the point of receiving therapy and over the longer-term once out of hospital.

The project will develop an electronic capture system to assess patient symptoms and quality of life when they receive these new therapies. Patients will be able to report how they feel on the treatment by using electronic devices. Any worrying symptoms will be flagged to the clinical team to help promote patient safety. These data will also be used to assess the effectiveness of treatment and be used as an evidence base for regulators and policy makers to support uptake in the NHS. Patients have been directly involved in development of the project and will provide direct input into the system development to ensure that it meets their needs.

The Datatrial Nucleus database platform being rolled out across the Advanced Therapy Treatment Centres in the UK will collect data from multiple sources and will be important in allowing assessments of cost-effectiveness of these therapies.

The project lead is the Midlands & Wales Advanced Therapy Treatment Centre (MW-ATTC) - a national centre of excellence in partnership with the Centre for Patient Reported Outcomes Research at The University of Birmingham, health technology companies Dignio and Datatrial. The project draws on expertise from stakeholders in the ATTC network, London's network of Advanced Therapy Centres (ATCs), the pharmaceutical industry including ATMP developers and producers such as Chiesi and Autolus, the Cell and Gene Therapy Catapult, UK regulators and payers.

Note: you can see all Innovate UK-funded projects here: <https://www.gov.uk/government/publications/innovate-uk-funded-projects>

Use the Competition Code given above to search for this competition's results

Results of Competition: Advanced Therapy Treatment Centres: Network Projects

Competition Code: 1806_ATTTC_NETWORK

Total available funding is £5.9m

Note: These proposals have succeeded in the assessment stage of this competition. All are subject to grant offer and conditions being met.

Participant organisation names	Project title	Proposed project costs	Proposed project grant
The Christie NHS Foundation Trust	Standard Approach to atMP tissue colLECTION (SAMPLE)	£265,076	£265,076
ASYMPTOTE LIMITED		£419,545	£209,772
AUTOLUS LIMITED		£433,350	£260,010
CELLULAR THERAPEUTICS LTD		£321,398	£224,979
Guy's and St Thomas' NHS Foundation Trust (GSTT)		£117,265	£117,265
Manchester University NHS Foundation Trust		£64,515	£64,515
NHS Blood and Transplant		£249,802	£249,802
Scottish National Blood Transfusion Service		£374,286	£374,286

Note: you can see all Innovate UK-funded projects here: <https://www.gov.uk/government/publications/innovate-uk-funded-projects>

Use the Competition Code given above to search for this competition's results

The Newcastle upon Tyne Hospitals NHS Foundation Trust	£110,194	£110,194
TRAKCEL LIMITED	£150,113	£105,079

Note: you can see all Innovate UK-funded projects here: <https://www.gov.uk/government/publications/innovate-uk-funded-projects>
Use the Competition Code given above to search for this competition's results

Project description - provided by applicants

Advance Therapy Medicinal Products (ATMPs) are a new generation of treatments which use patients' cells as 'drugs' to treat a variety of diseases. Although encouraging results have been reported, this technology is complex, expensive and currently only available to small numbers of patients.

In **2018** the **UK** have formed **a network of three Advanced Therapy Treatment Centres (ATTCs)** supported by the **Cell & Gene Therapy Catapult**. The ATTC network have partners made up of: ATMP developers & manufacturers, National Blood Services, Hospitals, Universities, logistics providers, raw materials suppliers & technology providers. This project is being led by the **iMATCH ATTC** (innovate Manchester Advanced Therapy Centre Hub) but involves collaboration with the other 2 ATTCs Midlands & Wales ATTC and Northern Alliance ATTC and introduces a new partner (Guy's & St Thomas's Hospital, London) to expand activities outside the ATTCs. This **Project** **"SAMPLE"** will harnesses a group of collaborators who share a vision of working more efficiently together so we can develop a standardised approach to the collection of tissue & cell based starting materials essential to the manufacture of Advanced Therapy Medicinal Products. Ultimately, making improvements enabling more life changing treatments to be provided to children and adults with cancer and non-cancer diseases.

This project unites experts from Scotland, England & Wales: NHS Blood & Transplant, SNBTS, The Christie NHS Foundation Trust, Manchester University NHS Foundation Trust, The Newcastle upon Tyne Hospitals NHS Foundation Trust and 4 businesses with specific expertise in different aspects of delivering Advanced Therapies. The 4 commercial partners are; Asymptote, Autolus, Cellular Therapeutics & TrakCel as well as 3 non-funded participation from global medicine manufacturers and technology providers: Novartis, Gilead & Terumo BCT.

We are going to focus on: coordinating patient cell collection, processing and storage of those cells and enabling efficient systems to collect **SAMPLES** from the patient or donor and so streamlining the manufacture and enabling an increase in the number of patients being treated.

The UK is a world leader in these types of treatments and this investment by Innovate UK will build on these innovative therapies and technologies thereby improving the lives of the UK population but also making the UK a destination for both investment and also other non-UK developed therapies in both trials and ultimately standard therapies.

Note: you can see all Innovate UK-funded projects here: <https://www.gov.uk/government/publications/innovate-uk-funded-projects>

Use the Competition Code given above to search for this competition's results